Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF D594G |
| Therapy | Erlotinib |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF D594G | lung adenocarcinoma | sensitive | Erlotinib | Case Reports/Case Series | Actionable | In a clinical case study, Tarceva (erlotinib) treatment resulted in a partial response with a 40% decrease in tumor lesions in a patient with lung adenocarcinoma with bone, pleural, and lymph node metastases harboring BRAF D594G, and in a preclinical analysis, Tarceva (erlotinib) inhibited the growth of a patient-derived cell line harboring BRAF D594G in 2D and 3D culture (PMID: 39637338). | 39637338 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39637338) | Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations. | Full reference... |